108 BioCapital
Overview
108 BioCapital is a private equity investment firm focused on growth-stage investments in biotech and medtech companies addressing high-impact, unmet medical needs.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Pinwheel Therapeutics | Feb 2026 | Series A | Lead |
| SedMed, Inc. | Oct 2026 | Early Funding | Lead |
| CellsBin | Sep 2026 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is 108 BioCapital based?
108 BioCapital is headquartered in Danbury, Connecticut, United States.
When was 108 BioCapital founded?
108 BioCapital was founded in 2025.
How many portfolio companies does 108 BioCapital have?
108 BioCapital has 3 portfolio companies in Caplight's dataset.
What are some companies in 108 BioCapital's portfolio?
Portfolio companies visible on Caplight include Pinwheel Therapeutics, SedMed, Inc., CellsBin.
What was 108 BioCapital's most recent investment shown here?
108 BioCapital's most recent investment in this portfolio sample was in SedMed, Inc. in 2026.
What sectors does 108 BioCapital focus on?
108 BioCapital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Consumer & Commerce.
What company stages does 108 BioCapital focus on?
Stage focus information for 108 BioCapital is not publicly available.
What is 108 BioCapital's AUM?
108 BioCapital's assets under management are estimated at over $40.0M.